To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.
Participants with the suspected of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision
Participants that have signed informed consent.
Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.
Healthy participants with no clinical diagnosis of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision.
Participants with primary clinical and pathological data missing.
Participants lost to follow-up.
Participants with too poor medical image quality to perform segment and mark ROI accurately
Patients the suspected of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision
Cohort
Prospective
Not listed
The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule)
The outcome of clinical diagnosis of patients with lung cancer/pulmonary nodular (Benign/Malignant nodule). ① Benign nodule ② Malignant neoplasm/nodule: squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and large cell carcinoma.
The outcome of clinical diagnosis of suspected patients with stomach cancer or lesion (Benign/Malignant).
① Benign ② Malignant
The outcome of clinical diagnosis of suspected patients with colorectal cancer or lesion (Benign/Malignant).
① Benign ② Malignant
Treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer (CR, PR, PD, SD).
The treatment response of anti-cancer therapy at first evaluation in patients with lung/stomach/colorectal cancer follows The Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) from the World Health Organization (WHO). The evaluation index is as follows. CR (complete response): Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to ≤10 mm. PR (partial response): 30% decrease in the sum of the longest diameter of the target lesions compared with baseline. PD (progressive disease):≥20% increase of at least 5 mm in the sum of the longest diameter of the target lesions compared with the smallest sum of the longest diameter recorded OR The appearance of new lesions, including those detected by FDG-PET (fludeoxyglucose positron emission tomography). SD (stable disease): Neither PR nor PD.
Click on the lead sponsor to view all of their trials.
